Thursday, November 05, 2026
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Overview. The third quarter was active for CoreCivic, with the Company delivering strong financial results, driven by increased demand from ICE, including higher utilization of recently activated facilities, as well as the contribution from the acquisition of Clinical Solutions Pharmacy earlier this year. In addition, CoreCivic completed the sale of four facilities to the Federal government, generating $2.2 billion in gross proceeds.
3Q26 Results. Revenue in 3Q totaled $744.1 million, up 28.2% y-o-y and exceeding our $690 million projections. Adjusted EBITDA in 3Q26 was $117.8 million, up 32.6% y-o-y and above our $109 million estimate. Adjusted EPS was $0.49, up over 100% y-o-y and exceeding our $0.42 per share projection.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.